MPX-004
MPX-004 is a pyrazine-containing GluN2A antagonist that selectively inhibits GluN2A-containing NMDA receptors. MPX-004 can be used as a tool to understand GluN2A physiology and involvement in neuropsychiatric and developmental disorders. GluN2A is the most abundant of the GluN2 NMDA receptor subunits in the mammalian CNS. Physiological and genetic evidence implicate GluN2A-containing receptors in susceptibility to autism, schizophrenia, childhood epilepsy and neurodevelopmental disorders such as Rett Syndrome.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD507 |
| CAS # | N/A |
| Pricing | Customizable size, Inquiry |
| Synonym | MPX-004; MPX004; MPX 004 |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C17H15ClFN5O3S2 |
| Exact Mass | 455.0289 |
| Molecular Weight | 455.91 |
| Elemental Analysis | C, 44.79; H, 3.32; Cl, 7.78; F, 4.17; N, 15.36; O, 10.53; S, 14.06 |
| IUPAC/Chemical Name | 5-(((3-chloro-4-fluorophenyl)sulfonamido)methyl)-N-((2-methylthiazol-5-yl)methyl)pyrazine-2-carboxamide |
| InChi Key | BRNKHERDLJYUNK-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H15ClFN5O3S2/c1-10-20-7-12(28-10)8-23-17(25)16-9-21-11(5-22-16)6-24-29(26,27)13-2-3-15(19)14(18)4-13/h2-5,7,9,24H,6,8H2,1H3,(H,23,25) |
| SMILES Code | O=C(C1=NC=C(CNS(=O)(C2=CC=C(F)C(Cl)=C2)=O)N=C1)NCC3=CN=C(C)S3 |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |
| Class-2 | Schizophrenia |